CD274 and neoplasm: Considering the dynamic role of platelets in tumor progression [68], the researchers attached the PD‐L1 antibody to the surface of platelets, using the tumor‐targeting ability of platelets and platelet‐activated derived particles to achieve tumor binding of the PD‐L1 antibody thus enhancing the tumor‐killing ability of T cells [69] (Figure 2A).